Thus, our findings provide a rationale for combined blockade of ITGB1 and ITGB4, with clinically available antibodies, as a promising therapeutic strategy for management of HCC intrahepatic metastasis. This evidence concerns the gene ITGB1 and hepatocellular carcinoma.